Cerus (CERS) Tops Q4 EPS by 2c, provides product guidance

Cerus (NASDAQ: CERS) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $53.34 million versus the consensus estimate of $53.62 million.

Reiterating 2024 Product Revenue Guidance

The Company expects full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8 million to $10 million.

For earnings history and earnings-related data on Cerus (CERS) click here.

You May Also Be Interested In

• Cerus (CERS) Tops Q3 EPS by 2c, offers product revenue guidance
• Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
• Upwork Inc. (UPWK) Tops Q3 EPS by 8c; Offer Guidance